Skip to Content

The Impact of Adding Nivolumab to First-Line Chemotherapy in Patients with Advanced Gastric Cancer

Nivolumab plus chemotherapy (Nivo-Chemo) is the standard treatment for advanced gastric cancer. However, real-world data on the efficacy of Nivo-Chemo are limited. In this MEDtalk, Dr. Mai Utsumi presents a study on the impact of adding nivolumab to first-line chemotherapy in patients with advanced gastric cancer.

Mai Utsumi

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top